Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Share Price Berne S.E.

Equities

BMY

US1101221083

Pharmaceuticals

Delayed Berne S.E.
Other stock markets
 17:00:01 21/02/2024 GMT 		5-day change 1st Jan Change
44.08 CHF +2.55% Intraday chart for Bristol-Myers Squibb Company -.--% -6.91%
06-07 Geron shares surge after U.S. FDA approves blood disorder drug RE
06-05 I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 46.09B 41.27B 3,623B Sales 2025 * 46.06B 41.24B 3,621B Capitalization 84.08B 75.3B 6,610B
Net income 2024 * -5.41B -4.85B -426B Net income 2025 * 10.22B 9.15B 803B EV / Sales 2024 * 2.67 x
Net Debt 2024 * 39.03B 34.96B 3,068B Net Debt 2025 * 31.68B 28.37B 2,490B EV / Sales 2025 * 2.51 x
P/E ratio 2024 *
-15.8 x
P/E ratio 2025 *
7.85 x
Employees -
Yield 2024 *
5.8%
Yield 2025 *
6.09%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Geron shares surge after U.S. FDA approves blood disorder drug RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients MT
Bristol Myers: positive results in liver cancer CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial CI
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company CI
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies MT
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting CI
Bristol Myers: presents advances in lung cancer CF
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer CI
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes RE
GSK blood cancer drug nearly halves risk of death in late-stage trial RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®? CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma MT
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma AQ
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial BU
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference BU
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting BU
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : résultats positifs dans le cancer du foie
Bristol Myers : présente ses avancées en cancer du poumon
Bristol Myers : approbation de la FDA pour Breyanzi
Bristol Myers : nouvelle approbation de la CE pour Opdivo
Bristol Myers : présentera des données sur la schizophrénie
More news

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 31/01/15
David Elkins DFI
 Director of Finance/CFO 55 19/11/19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19/11/19
Peter Arduini BRD
 Director/Board Member 59 31/03/16
Derica Rice BRD
 Director/Board Member 59 31/08/20
More insiders

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
11/06/2024 - Goldman Sachs Global Healthcare Conference
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48 USD
Average target price
53.19 USD
Spread / Average Target
+28.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
NOVARTIS AG Stock Novartis AG
+11.88% 216B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMY Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW